Tag Archives: Bioscience Roadmap

bioscience

What would you do with a billion dollars?

Last week, Representative Bob Robson , Speaker pro tempore of the Arizona House of Representatives introduced House Bill 2033 which would create a funding vehicle to enable our universities to maintain and expand our research infrastructure at that level.

At a time when the state is projecting a $500 million budget shortfall in fiscal 2014-15 and projected $1 billion shortage in the following fiscal year, some people might say that making bold investments at a time when dollars are tight is something we cannot afford to do. Yet, if we are truly committed to building a diversified and stronger economy, one that will benefit our state today and into the future, we can’t afford not to.

It was Robson’s bill in 2003 that made $500 million worth of financing available for the construction of new research facilities at our universities including the ASU Biodesign Institute, UA BIO5, Research Facilities at NAU, components of the Phoenix Biomedical Campus, and more. Economic analysis of this initial investment has shown that each dollar invested generated seven dollars in return.

These facilities and the work that occurs within their walls serve as a magnet to attract great talent. These facilities are places where our students gain the practical experience that will enable them to become our future leaders. These facilities are the place where we begin the process of discovery, development, and delivery that leads to the creation of life changing innovations that will benefit people here in Arizona and around the world.

Since the creation of these facilities, Arizona’s Bioscience Industry has grown. Jobs in bioscience related fields have increased by 45 percent, nearly four times greater than the nation. While not every one of these jobs is directly related to our university research infrastructure, all of them depend on both it and the credibility is gives to our growing bioscience sector which in 2014 again moved up in the national rankings.

In 2014, the Flinn Foundation published the second generation of the Arizona Bioscience Roadmap, a renewed commitment and a plan developed collaboratively by leaders from across Arizona. In its opening pages it reads:

“To achieve the Roadmap’s vision, five transformative steps are recommended: make risk capital more readily available to Arizona’s early-stage bioscience firms; boost the research revenues of the state’s research-performing institutions; further develop the research infrastructure at the state universities; attract industry and research anchors; and develop ties to economic partners in neighboring markets. Achieving these steps will require a profound increase in investment, primarily from the private sector but with key public-sector investments playing a necessary and vital role. Going forward, Arizona should continue its strategy to focus resources and efforts on areas where it excels.”

It is not the State of Arizona’s job to accomplish all of these things. It will take all of us, working together, reaching out nationally and internationally, and in ways that are both creative and sustainable.

Representative Robson has again offered us a catalyst for innovation and economic growth. In science, a catalyst is a substance that speeds up a chemical reaction, but is not consumed by the reaction; hence a catalyst can be recovered chemically unchanged at the end of the reaction it has been used to speed up, or catalyze. HB2033 crates an economic catalyst which when it becomes law can generate the energy and economic impact we need to take our economy and our state to new levels of success, and through its design be recovered through the economic gains it will create.

Instead of lamenting on what we don’t have, it’s time to build on what we do. Now is our opportunity, as industry and as Arizonans, to get behind HB 2033 and catalyze strategic investments in Arizona’s future.

Joan Koerber-Walker is President and CEO of the Arizona Bioindustry Association and Chairman of the State Medical Technology Alliance in Washington, D.C.

bioscience

Jewett Named Arizona Bioscience Leader of the Year

jewett-sqJack B. Jewett, President & CEO of the Flinn Foundation, will be honored with the Jon W. McGarity Arizona Bioscience Leader of the Year Award by the Arizona BioIndustry Association.

“Great leaders embrace possibilities and take the steps to make them reality. Jack B. Jewett has done more than just take steps,” shared Joan Koerber-Walker, President & CEO, of the Arizona Bioindustry Association. “Thanks to his leadership and the commitment of the Flinn Foundation, Arizona has a Bioscience Roadmap that charts our statewide bioscience strategies through 2025.”

A longtime Arizona leader in health care, education, and public policy, Mr. Jewett joined the Flinn Foundation in June 2009 as President & CEO. In this role, he is responsible for all grant programs and operations of the Flinn Foundation including Arizona’s Bioscience Roadmap, which is the longest running bioscience strategic initiative of its kind in the US. Under Jewett’s leadership, Flinn has renewed its commitment and released the next generation of the Roadmap extending out until 2025.

Mr. Jewett previously served in a variety of leadership roles within the private, public, and nonprofit sectors in Arizona for more than 40 years. He held senior public policy and government relations positions with Tucson Medical Center for 13 years and served as president of Territorial Newspapers, a family-owned publishing and printing company in Tucson. He served on the Arizona Board of Regents from 1998-2006, including a term as president; and five terms in the Arizona House of Representatives, from 1983-1992, the final two years as majority whip.

A University of Arizona graduate, Mr. Jewett currently serves on the board of trustees of the Tucson-based Thomas R. Brown Foundations, is a public member of the Arizona Judicial Council, and is a member of the Greater Phoenix Leadership Council. He served on the board of directors for the National Association of Governing Boards of Universities and Colleges from 2004-13, and received its Distinguished Service Award for outstanding trusteeship for his work on “Changing Directions,” an initiative of the Arizona Board of Regents.

The Flinn Foundation is a privately endowed, philanthropic grantmaking organization established in 1965 by Dr. Robert S. and Irene P. Flinn to improve the quality of life in Arizona to benefit future generations. Today, the Foundation supports the advancement of the biosciences in Arizona, as well as three other program areas to help build Arizona’s knowledge-driven economy.

A ceremony honoring Jack B. Jewett will take place at the AZBio Awards Sept. 17 at the Phoenix Convention Center. The AZBio Awards ceremony celebrates Arizona’s leading educators, innovators and companies. Each year, AZBio honors bioindustry leaders from across the state of Arizona who are illustrative of the depth, breadth and expertise of our bioscience industry.

Past recipients of the Jon W. McGarity Arizona Bioscience Leader of the Year Award include: Linda Hunt (Dignity Health), Harry George (Solstice Capital), Robert Penny, MD, PhD (International Genomics Consortium), Patrick Soon-Shiong, MD (NantHealth), Martin L. Shultz (Pinnacle West Capital Corp.), Michael Cusanovich, Ph.D., (University of Arizona), Jonathan Thatcher (Exeter Life Sciences), John W. Murphy (Flinn Foundation), and George Poste (Arizona State University).

For registration and more information, go to www.azbio.awards.com.

bioscience

Bioscience Roadmap gets an extension through 2025

The strategic plan that has guided Arizona’s fast-growing bioscience sector for nearly 12 years is gearing up for a new decade.

“Arizona’s Bioscience Roadmap: 2014-2025” will be unveiled starting April 8 at events in Phoenix, Tucson, and Flagstaff, the state’s three metropolitan areas that feature growing bioscience hubs. The plan includes updated strategies that can strengthen and diversify Arizona’s economy while providing Arizonans access to the latest health care innovations.

“The updated Bioscience Roadmap builds on the successes of its first decade and adds contemporary strategies to take Arizona’s bioscience base to the next level,” said Jack Jewett, President & CEO of the Flinn Foundation, which commissioned the update and the original Bioscience Roadmap in 2002. “Arizona is now known as a top emerging bioscience state, but we have far to go to reach our full potential.”

The updated Roadmap will continue to focus on developing Arizona’s biomedical research infrastructure but will emphasize turning this research into new therapies, products, diagnostics, jobs, firms, and other benefits to Arizona. Commercialization, entrepreneurship, creating a critical mass of bioscience firms, and the development of talent are prime themes.

The Roadmap’s overarching vision is for Arizona—a young but rapidly growing state in the biosciences—to become a global competitor and national leader in select areas of the biosciences by 2025.

Over the first decade, Arizona built major research facilities at its universities, formed new private research institutes, attracted top talent, created high-tech business incubators, and greatly expanded statewide STEM (science, technology, education, math) education programs. The number of Arizona bioscience industry jobs grew by 45 percent, nearly four times greater than the nation.

“Arizona has many bioscience strengths and opportunities, but a substantial increase in private and public investment will be needed over the next decade to realize the Roadmap’s goals,” said Walter Plosila, senior advisor to the Battelle Technology Partnership Practice, the Columbus, Ohio-based nonprofit research and development organization that authored the original Roadmap and its update.

Plosila noted that Arizona’s greatest needs are access to risk capital by startup and emerging bioscience firms, building a stronger bioscience entrepreneurship culture, and an expansion of the research infrastructure combined with commercialization at the state’s universities.

The new Roadmap plan features five goals, 17 strategies, and 77 proposed actions. The actions are meant to evolve as needs change over the course of the decade. The plan was developed by Battelle following research, interviews, and focus groups with more than 150 local and national bioscience leaders, including extensive input from Arizona’s Bioscience Roadmap Steering Committee, a body of more than 100 statewide leaders in science, business, academia, and government.

“An emphasis on the full spectrum of the biosciences—from research to hospitals to bio-agriculture—and a renewed focus on resources, collaboration, and long-term patience is needed for Arizona to continue its ascent in the biosciences,” said Martin Shultz, Senior Policy Director for Brownstein Hyatt Farber Schreck, who chairs the Roadmap Steering Committee. “The impact can be profound—the biosciences are a multibillion-dollar industry for Arizona.”

There are six industry segments that comprise the biosciences in Arizona: agricultural feedstock and chemicals; drugs, pharmaceuticals, and diagnostics; medical devices and equipment; research, testing, and medical labs; bioscience-related distribution; and hospitals. A new economic-impact analysis by Battelle estimates the total revenue generated annually by Arizona’s bioscience industry—not counting hospitals—to be $14 billion. With hospitals included, the figure exceeds $36 billion.

Based on the latest industry data (2012), Arizona currently has 106,846 bioscience jobs spread across 1,382 establishments and an annual average wage of $62,775—39 percent higher than the private-sector average. These numbers do not include academic research jobs at the state universities or private research institutes.

Hospitals account for the majority of the state’s bioscience jobs. With hospitals removed from the equation, the other segments combine for 23,545 jobs, 1,266 establishments, and average annual wages of $85,571. Growth in the non-hospital segments accelerated dramatically over the last few years.

The bioscience-related distribution subsector is a new addition to Arizona’s bioscience definition, following the lead of the Biotechnology Industry Organization, the nation’s bioscience trade association. Companies in this subsector coordinate the delivery of bioscience-related products through processes such as cold storage and product monitoring, and new technologies such as automated pharmaceutical distribution systems. This change also called for several smaller industries to be dropped from Arizona’s definition.

The Roadmap also presents updated data on Arizona’s performance in generating grants from the National Institutes of Health, academic research expenditures, venture capital, and tech-transfer measures involving the state universities. These metrics plus industry measures will be tracked throughout the decade by Battelle and reported by the Flinn Foundation.

The Roadmap also includes analyses of Arizona’s bioscience sector that were critical in developing the strategies and actions, such as an assessment of Arizona’s bioscience strengths, weaknesses, opportunities, and challenges. It identified Arizona’s core competencies as cancer research, neurosciences, bioengineering, agricultural biotechnology, imaging sciences, precision medicine, diagnostics, health information technologies, and health economics.

The Flinn Foundation is a privately endowed, philanthropic grantmaking organization established in 1965 by Dr. Robert S. and Irene P. Flinn to improve the quality of life in Arizona to benefit future generations. The Phoenix-based foundation supports the advancement of the biosciences in Arizona, as well as a merit-based college scholarship program, arts and culture, and the Arizona Center for Civic Leadership. “Arizona’s Bioscience Roadmap: 2014-2025” is available for download at www.flinn.org.

pharmaceuticals

Arizona bioscience job growth outpaces nation

Arizona’s bioscience sector added jobs at nearly four times the national rate over the past decade and experienced double-digit job growth during the economic recovery, a new report shows.

Since Arizona’s Bioscience Roadmap was launched in 2002, Arizona’s bioscience jobs have increased by 45 percent to 99,018 in 2011. Nationally, the growth rate during this time was 12 percent. While hospitals dominate Arizona’s bioscience jobs, the state’s non-hospital subsectors grew 14 percent in 2011 alone.  During the economic recovery years of 2009-11, the state’s bioscience jobs increased 11 percent while there was no gain across the state’s private sector.

The new performance analysis of Arizona’s bioscience sector, commissioned by the Flinn Foundation, also found that the number of bioscience establishments in Arizona continues to grow faster than the national average and bioscience wages in the state are outpacing those in other private-sector industries.

The 10th-annual study, released Feb. 5 by the Battelle Technology Partnership Practice, did reveal funding challenges for the state.  In 2012, Arizona fell to its lowest venture capital investment level since 2009 and suffered a drop in National Institutes of Health funding while the top-10 funded states advanced.

“Arizona’s bioscience sector continues to significantly outperform the nation in terms of job and establishment growth and has made impressive gains in building a more concentrated industry base,” said Walter Plosila, senior advisor to the Battelle Technology Partnership Practice.  “However, more attention must be paid to academic research performance and venture capital investment to continue the trend in years to come.”

Plosila added that progress has been made over the past decade on all 19 actions recommended by Battelle in 2002, including substantial progress on nine.

The Roadmap was launched in 2002 as a long-range plan to make the state’s bioscience sector globally competitive. The Roadmap was commissioned by the Phoenix-based Flinn Foundation, which committed to 10 years of major funding of Arizona biosciences and formed a network of committees involving statewide experts to implement its recommendations.

There was also a major increase in bioscience establishments, rising 31 percent since 2002 to 892 firms, which is above the national growth rate of 23 percent.

Bioscience jobs in Arizona pay an average salary of $56,328, or 28 percent higher than the $44,098 for all private-sector industries. Since 2002, bioscience salaries have increased 44 percent.

“After 10 years, Arizona has carved a niche in the highly lucrative and competitive biosciences field,” said Martin Shultz, chair of Arizona’s Bioscience Roadmap Steering Committee. “We’re one of the nation’s top emerging bioscience states, and our growth in high-wage jobs continued during both good economic times and bad.”

In terms of research dollars, NIH funding in 2012 was $174 million, or 19 percent greater, than the 2002 figure. This is a decrease from $184 million in 2011. While NIH funding, the gold standard for biomedical research funding, did increase slightly faster than the national average of 18 percent over the past decade, Arizona is no longer meeting its goal of obtaining funding at a growth rate higher than the top-10 funded states. In addition, its share of the funding pool remains nearly the same as it was in 2002.

The latest data also shows:
•    The largest non-hospital bioscience subsector continues to be research, testing and medical laboratories. This group now boasts about 8,900 workers across 466 establishments, roughly a 60 percent increase in both employees and firms since 2002. The other subsectors are drugs, pharmaceuticals and diagnostics; hospitals; medical devices and equipment; and agricultural feedstock and chemicals.
•    Venture capital investment was $22 million in 2012, which is the lowest figure since 2009. This was a drop of 68 percent from 2011, compared with a national decline of 49 percent.
•    Bioscience-related academic research and development expenditures at Arizona’s universities reached a record $452 million in 2011, a 55 percent increase since 2002. Arizona’s growth had outpaced the nation until 2009, but now trails the overall U.S. growth rate of 74 percent.
•    Arizona universities spun out seven bioscience companies in 2012. University discoveries have now led to 67 new bioscience startups since 2002 as well as 180 bioscience patents.

There were a number of major developments in 2012 that showed the collaborative nature of Arizona biosciences, including the completion of major projects, the approval of future pursuits, and an emphasis on education.

The University of Arizona opened its new Health Sciences Education Building on the Phoenix Biomedical Campus that enabled the UA College of Medicine-Phoenix to increase enrollment and for Northern Arizona University to begin Phoenix-based physician assistant and physical therapy programs. In addition, final approval was granted by the Arizona Board of Regents for the UA Cancer Center-Phoenix to be built on the same campus in partnership with St. Joseph’s Hospital and Medical Center.

A number of incubators and accelerators opened or expanded with more in the planning stages. BioInspire, an incubator for medical-device startups, opened in Peoria; GateWay Community College in Phoenix opened the Center for Entrepreneurial Innovation; the Arizona Center for Innovation at the UA Science and Technology Park in Tucson opened upgraded facilities and launched new programming; Flagstaff received funding for a planned accelerator; and the statewide Arizona Furnace accelerator began awarding seed money and access to incubation space.

Among other major developments, the inaugural Arizona SciTech Festival attracted 200,000 participants from across the state during February and March 2012, making it one of the largest in the nation; Banner Alzheimer’s Institute launched a $100 million trial to prevent or delay Alzheimer’s disease; a new skin-cancer drug first tested by Translational Genomics Research Institute and Scottsdale Healthcare received expedited approval from the Food and Drug Administration; Arizona State University began leading the first national algae biofuel testbed; Mayo Clinic announced plans for a new cancer center on its north Phoenix campus; and Banner MD Anderson Cancer Center in Gilbert announced a $63 million expansion.

On Dec. 4, 2012, the Flinn Foundation and bioscience leaders from across Arizona came together at the Arizona Biltmore to celebrate the 10th anniversary of the launching of Arizona’s Bioscience Roadmap. The Foundation announced it has committed to continue funding Arizona biosciences and coordinating the Roadmap as it enters its next chapter.

“We recognize this is a long-term pursuit,” said Jack Jewett, president and CEO of the Flinn Foundation. “We will continue to strive to improve the lives of Arizonans today and tomorrow through new medical discoveries, access to clinical trials and the recruitment of top researchers, while also attracting high-wage jobs that will strengthen Arizona’s economy.”

The Flinn Foundation is a Phoenix-based, private, nonprofit philanthropic endowment. It was established by Dr. and Mrs. Robert S. Flinn in 1965 with the mission of improving the quality of life in Arizona to benefit future generations. The nonprofit philanthropy supports the advancement of Arizona’s bioscience sector, the Flinn Scholars program, arts and culture, and the Arizona Center for Civic Leadership.

srp installs solar energy systems

Energy Consortium’s Roadmap puts state of path to build industry

Imagine Arizona as the energy hub of the Southwest — where major regional transmission lines tie into infrastructure in the state and serve a growing regional demand for energy. Arizona would be a place where an increasing percentage of jobs are related to the energy industry, whether in manufacturing, generation, transmission, energy efficiency, service or technology innovation. Many of these jobs would be higher-wage jobs requiring a skilled labor force fed by Arizona’s schools and universities. Arizona could be a hub of energy-sector jobs, with factories making equipment for the industry and power plants shipping electricity to neighboring states via new power lines, all contributing to a better economy.

That is the essence of the Arizona Energy Consortium’s Energy Roadmap, which the group hopes with be a catalyst for the state’s energy industry in the same way Arizona’s Bioscience Roadmap helped the state increase bioscience jobs by 41 percent and helped increase the number of bioscience establishments by 27 percent during its 10-year plan.

“It was important to create this document to give the energy industry a unified voice and direction,” said said Michelle De Blasi, co-chair of the AEC and a shareholder at Greenberg Traurig. “The energy industry is going to be here forever. We are always going to need energy. So the Roadmap was designed to make the industry better for everyone — consumers, developers, legislators. So it was critical that we get it right.”

This is the vision the Roadmap hopes to realize over the next decade: Arizona is the energy hub of the Southwest, with a diverse energy mix supporting reliable transmission, a strong base of manufacturing facilities, increased numbers of higher wage jobs, and world-class research institutions, resulting in increased economic development for the state and region.

Once that vision is realized, De Blasi said the state can expect to reap these benefits:
• Enhanced job creation and higher-wage jobs within Arizona
• Increased state economic revenue
• Enhanced energy export potential
• Heightened energy self-sufficiency and national and state security
• Increased transmission reliability
• Continued low cost energy

“This Roadmap is going to help Arizona be looked at differently from outside its borders,” said Chris Davey, co-chair with De Blasi of the AEC and president of EnviroMission, which is developing a solar tower in Western Arizona. “The Roadmap will create a sense of certainty, which appeals to the finance community. So when they are looking to invest, that certainty creates a more attractive environment for developers and investors.”

Davey and De Blasi said they will be rolling out the Roadmap this year, presenting it to groups throughout the state. For more information on the Roadmap, visit aztechcouncil.org.

ROADMAP CONTRIBUTORS

Arizona Commerce Authority
Arizona Governor’s Office of Energy Policy
Arizona Public Service
Bridge Strategy Group
Brownstein Hyatt Farber Schreck
City of Mesa, the Office of the Mayor
Cleantech Open
Dircks
DIRTT
DMB Associates
Energy Services Coalition
EnviroMission
Faithful+Gould
Greater Phoenix Economic Council
Greenberg Traurig
The Green Chamber – Greater Phoenix
Golder Associates
Hensel Phelps
Ikoloji
Institute for Tribal Environmental Professionals
J.D. Porter & Associates
Kolbe Connect
Matthew McDonnell
Ormond Group, LLC
RG Schmelzer, Inc.
Salt River Project
Stream Energy
Tucson Electric Power
Valley Forward
Valley Partnership